Nicholas Marston, MD, MPH assistant professor of medicine, and a cardiologist at Brigham and Women's Hospital, presented the late-breaking VESALIUS-CV data on the use of evolocumab for the reduction of major cardiovascular events in patients who do not have significant atherosclerosis. #ACC26

Evolocumab reduces risk of major cardiac events in diabetic patients

Late-breaking data out of ACC.26 suggest a more aggressive treatment approach for these patients could be beneficial. 

Compensation for U.S. cardiologists is up across the board, according to a recent survey published by MedAxiom, an American College of Cardiology company. The report identified similar trends for cardiovascular surgeons, highlighting the country’s high demand for all heart specialists in 2024 and beyond.

How to prevent the most common complication after heart surgery

The Society of Thoracic Surgeons put together an expert committee to examine the prevention and treatment of new-onset postoperative atrial fibrillation after cardiac surgery. The group shared recommendations for before, during and after treatment.

Heart Rhythm 2025 Heart Rhythm Society President Kenneth A. Ellenbogen, MD

Heart Rhythm 2026 to feature late-breaking EP data, hands-on training and more

Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.

Gregg Stone, MD, FACC, FSCAI, Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai Hospital in New York, presented the results of the long-awaited STEMI Door or Unloading time trial, which takes a different approach to first using a percutaneous heart pump to unload the heart 30 minutes prior to PCI interventions to try and prevent common complications and improve outcomes.

Late-breaking PCI data challenge the 'time is muscle' paradigm

Gregg Stone, MD, spoke to Cardiovascular Business about the lessons he and his colleagues learned from the STEMI DTU trial.

artificial intelligence consultation

Another win for opportunistic screening: AI turns head CT scans into heart assessments

AI can help care teams get additional value out of routine head CT images.

One of the big late-breaking trials presented at the 2026 American College of Cardiology (ACC) Scientific Sessions was the CHAMPION-AF, which showed left atrial appendage occlusion (LAAO) can offer a safe, non-drug alternative to anticoagulation therapy, even in patients with atrial fibrillation who are not at high risk for bleeding. First author of the study Shephal Doshi, MD, FACC, an electrophysiologist at Cedars Sinai Smidt Heart Institute, discussed the details of the trial. #LAAO #ACC #ACC26

New data point to LAAO as a safe alternative to long-term drug therapy

At the end of the day, one electrophysiologist explained, these decisions should still be made on a case-by-case basis.

heart drugs with stethoscope

Long-term antidepressant use may increase risk of sudden cardiac death

The risk appears to be greatest when patients are still actively taking antidepressants. Researchers noted that many more studies on this topic are still necessary.

Video interview with Society for Cardiovascular Angiography and Interventions (SCAI) President Srihari S. Naidu, MD, FACC, FAHA, MSCAI, explains the advancements in interventional cardiology the society has championed over the past year. #SCAI

Outgoing SCAI president reflects on a busy year full of partnerships and advocacy

SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, made a major impact on the group—and cardiology as a whole—over the last 12 months.